Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.52 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917730 | 1.00 | CACNA2D1 (0.52) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27084647 | 0.84 | GABRP (0.48) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5972500 | 0.83 | CACNA2D1 (0.52) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27752647 | 0.83 | SLC7A5 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27752648 | 0.83 | SLC7A5 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5509924 | 0.81 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5516291 | 0.81 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5187938 | 0.81 | CACNA2D1 (0.38) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL21585492 | 0.79 | CACNA2D1 (0.46) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27591715 | 0.79 | GABRP (0.39) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4681116-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| EP-1009399-B1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER LAMBERT CO (US) | 2010-03-24 | — | — | EP | claimed |
| JP-3884486-B2 | — | — | 2007-02-21 | — | — | JP | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | claimed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | claimed |
| EP-0994704-B1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER LAMBERT CO (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1515709-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | Warner-Lambert Company LLC (US) | 2005-03-23 | — | — | EP | claimed |
| JP-2002506449-A | — | — | 2002-02-26 | — | — | JP | claimed |
| US-6329429-B1 | ADMINISTERING ANTI-INFLAMMATORY COMPOUND COMPRISING CYCLIC AMINO ACID OR ITS DERIVATIVE TO THERAPY | WARNER-LAMBERT COMPANY | 2001-12-11 | — | — | US | claimed |
| US-20010014698-A1 | Method for preventing and treating alcoholism | BUENO LIONEL (FR) | 2001-08-16 | — | — | US | claimed |
| US-6127418-A | USING, E.G. PREGABALAN, GAGAPENTIN, FOR A PATIENT WHO IS OR WILL RECEIVE NSAID THERAPY OR ALCOHOL ABUSE THERAPY; INFLAMMATORY BOWEL DISORDER; IRRITABLE BOWEL SYNDROME; CROHN'S DISEASE, ILEITIS, ISCHEMIC BOWEL DISEASE | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | claimed |
| EP-1009399-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY LLC (US) | 2000-06-21 | — | — | EP | claimed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| EP-0974351-A2 | Medicament for preventing and treating gastrointestinal damage | JOUVEINAL (FR) | 2000-01-26 | — | — | EP | claimed |
| WO-1999008671-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| WO-1999008670-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | GUGLIETTA, ANTONIO | 1999-02-25 | — | — | WO | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014698-A1 | Method for preventing and treating alcoholism | ADH1A, GABRB3, GABRB2 | CACNA2D1 700/4885CACNB3 47/4885CACNA1C 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.